Covid-19 - The search for effective therapy

New England Journal of Medicine

Volumn 382, Issue 19, 2020, Pages 1851-1852

  Baden, Lindsey R ^a   Rubin, Eric J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; RITONAVIR;

ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; EDITORIAL; EPIDEMIC; EXTRACORPOREAL OXYGENATION; HUMAN; PATIENT CARE; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; BETACORONAVIRUS; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; LOPINAVIR; PANDEMICS; PNEUMONIA, VIRAL; RITONAVIR;

EID: 85082870649     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe2005477     Document Type: Editorial

References (4)

1. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Comm 2020;11:222.
2. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:1787-99.
3. Baden LR, Rubin EJ, Morrissey S, Farrar JJ, Drazen JM. We can do better - improving outcomes in the midst of an emergency. N Engl J Med 2017;377:1482-4.
4. Lopinavir/ritonavir (Kaletra). North Chicago, IL: AbbVie, 2019 (https://www.rxabbvie.com/pdf/kaletracap_PI.pdf) (prescribing information).